Niccola Funel

List of Publications by Year in Descending Order

87 papers	3,659 citations	31 h-index	59 g-index
91 ext. papers	4,206 ext. citations	6.4 avg, IF	4.56 L-index

#	Paper	IF	Citations
87	Detailing the ultrastructure increase of prion protein in pancreatic adenocarcinoma. *World Journal of Gastroenterology*, **2021**, 27, 7324-7339	5.6	0
86	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. *Cancers*, **2021**, 13,	6.6	4
85	Silver Nanoparticle-Coated Polyhydroxyalkanoate Based Electrospun Fibers for Wound Dressing Applications. *Materials*, **2021**, 14,	3.5	4
84	Prognostic impact of conservative surgery for pancreatic IPMNs. *Surgical Oncology*, **2021**, 38, 101582	2.5	2
83	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 2342-2345	4	1
82	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. *British Journal of Cancer*, **2020**, 123, 644-656	8.7	15
81	Triticum vulgare Extract Modulates Protein-Kinase B and Matrix Metalloproteinases 9 Protein Expression in BV-2 Cells: Bioactivity on Inflammatory Pathway Associated with Molecular Mechanism Wound Healing. *Mediators of Inflammation*, **2020**, 2020, 2851949	4.3	3
80	A Model of a Zebrafish Avatar for Co-Clinical Trials. *Cancers*, **2020**, 12,	6.6	24
79	3-(6-Phenylimidazo [2,1-][1,3,4]thiadiazol-2-yl)-1-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. *Molecules*, **2020**, 25,	4.8	22
78	Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. *European Journal of Medicinal Chemistry*, **2020**, 189, 112088	6.8	32
77	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. *JCI Insight*, **2020**, 5,	9.9	17
76	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. *World Journal of Gastroenterology*, **2020**, 26, 2792-2809	5.6	12
75	Robotic-assisted versus open left pancreatectomy for cystic tumours: A single-centre experience. *Journal of Minimal Access Surgery*, **2020**, 16, 66-70	1.2	3
74	The occurrence of prion protein in surgically resected pancreatic adenocarcinoma. *Pancreatology*, **2020**, 20, 1218-1225	3.8	3
73	Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report. *BMC Surgery*, **2020**, 20, 331	2.3	2
72	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. *Annals of Surgery*, **2020**, 271, 1137-1147	7.8	23
71	The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. *Seminars in Cancer Biology*, **2020**, 60, 238-248	12.7	26

70	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. *Cancers*, **2019**, 11,	6.6	11
69	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919841233	5.4	21
68	Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. *Cancers*, **2019**, 11,	6.6	33
67	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. *Biochemical Pharmacology*, **2019**, 166, 128-138	6	9
66	A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status. *Surgical Endoscopy and Other Interventional Techniques*, **2019**, 33, 234-242	5.2	20
65	Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. *Anticancer Research*, **2019**, 39, 3609-3614	2.3	4
64	New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. *Expert Review of Clinical Pharmacology*, **2019**, 12, 1081-1090	3.8	12
63	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. *EBioMedicine*, **2019**, 39, 215-225	8.8	27
62	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. *International Journal of Cancer*, **2019**, 144, 1275-1283	7.5	22
61	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. *Pharmacogenomics*, **2019**, 20, 49-68	2.6	18
60	Myoclonus epilepsy, retinitis pigmentosa, leukoencephalopathy and cerebral calcifications associated with a novel m.5513G>A mutation in the MT-TW gene. *Biochemical and Biophysical Research Communications*, **2018**, 500, 158-162	3.4	4
59	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. *Nature Communications*, **2018**, 9, 556	17.4	103
58	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. *Carcinogenesis*, **2018**, 39, 360-367	4.6	12
57	TGF-□nduces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. *Nature Communications*, **2018**, 9, 1845	17.4	61
56	Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells. *PLoS ONE*, **2018**, 13, e0197493	3.7	7
55	5□nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. *Oncotarget*, **2018**, 9, 16437-16450	3.3	6
54	Pancreatoduodenectomy without Vascular Resection in Patients with Primary Resectable Adenocarcinoma and Unilateral Venous Contact: A Matched Case Study. *Gastroenterology Research and Practice*, **2018**, 2018, 1081494	2	1
53	Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. *Journal of Hematology and Oncology*, **2017**, 10, 9	22.4	48

52	SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. *Scientific Reports*, **2017**, 7, 43812	4.9	11
51	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. *Scientific Reports*, **2017**, 7, 44686	4.9	36
50	Robotic pancreatoduodenectomy with vascular resection. *Langenbecks Archives of Surgery*, **2016**, 401, 1111-1122	3.4	39
49	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter. *Clinical Cancer Research*, **2016**, 22, 2594	12.9	
48	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. *Oncotarget*, **2016**, 7, 28556-69	3.3	16
47	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. *World Journal of Gastroenterology*, **2016**, 22, 6987-7005	5.6	52
46	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. *Scientific Reports*, **2016**, 6, 39565	4.9	9
45	Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. *Carcinogenesis*, **2016**, 37, 957-64	4.6	13
44	Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. *European Radiology*, **2015**, 25, 751-9	8	41
43	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. *European Journal of Cancer*, **2015**, 51, 1389-404	7.5	80
42	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nature Genetics*, **2015**, 47, 911-6	36.3	171
41	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. *Lancet, The*, **2015**, 385 Suppl 1, S37	40	41
40	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. *Clinical Epigenetics*, **2015**, 7, 129	7.7	16
39	TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. *International Journal of Cancer*, **2015**, 137, 2175-83	7.5	46
38	Pancreatic cancer. *Gastroenterology Research and Practice*, **2015**, 2015, 809036	2	2
37	Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice. *European Journal of Pharmacology*, **2014**, 729, 37-44	5.3	6
36	Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. *Journal of the National Cancer Institute*, **2014**, 106, djt346	9.7	39
35	miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. *Nucleosides, Nucleotides and Nucleic Acids*, **2014**, 33, 384-93	1.4	45

34	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nature Genetics*, **2014**, 46, 994-1000	36.3	226
33	AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. *PLoS ONE*, **2014**, 9, e108057	3.7	19
32	Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. *Biomatter*, **2014**, 4, e955386		32
31	A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. *Pharmacogenomics*, **2014**, 15, 609-18	2.6	9
30	Expression of SP7, RUNX1, DLX5, and CTNNB1 in human mesenchymal stem cells cultured on xenogeneic bone substitute as compared with machined titanium. *Implant Dentistry*, **2014**, 23, 407-15	2.4	3
29	Advances in Primary Cell Culture of Pancreatic Cancer **2014**, 11-38		
28	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. *Digestive and Liver Disease*, **2014**, 46, 479-93	3.3	90
27	MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. *Gastroenterology*, **2014**, 146, 268-77.e18	13.3	125
26	Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/Ecatenin signalling in pancreatic adenocarcinoma. *Oncotarget*, **2014**, 5, 5335-49	3.3	40
25	Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. *Current Drug Targets*, **2014**, 15, 1331-40	3	16
24	Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. *Digestive and Liver Disease*, **2013**, 45, 95-9	3.3	34
23	Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. *Current Pharmaceutical Design*, **2013**, 19, 940-950	3.3	46
22	Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. *Cancer Research*, **2013**, 73, 6745-56	10.1	65
21	Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment. *PLoS ONE*, **2013**, 8, e64863	3.7	29
20	Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. *Current Pharmaceutical Design*, **2013**, 19, 940-50	3.3	20
19	Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma. *Pharmaceutical Research*, **2012**, 29, 2601-14	4.5	67
18	The odd case of a small and mucinous-like acinar cell cystoadenocarcinoma of the pancreas. *Pancreatology*, **2012**, 12, 421-2	3.8	3
17	Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. *Clinical Cancer Research*, **2012**, 18, 524-33	12.9	19

16	High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. *PLoS ONE*, **2012**, 7, e49145	3.7	57
15	Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. *Molecular Cancer Therapeutics*, **2012**, 11, 1735-46	6.1	73
14	Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions. *Pancreatology*, **2011**, 11, 30-42	3.8	11
13	Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. *Expert Review of Molecular Diagnostics*, **2011**, 11, 695-701	3.8	20
12	Magnetic carbon nanotubes: a new tool for shepherding mesenchymal stem cells by magnetic fields. *Nanomedicine*, **2011**, 6, 43-54	5.6	28
11	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. *Pharmacogenomics*, **2011**, 12, 1641-52	2.6	36
10	Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. *Journal of Nephrology*, **2011**, 24, 381-5	4.8	6
9	Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. *PLoS ONE*, **2010**, 5, e12653	3.7	11
8	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. *Cancer Research*, **2010**, 70, 4528-38	10.1	361
7	Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. *Pancreatology*, **2010**, 10, 545-52	3.8	14
6	Multidetector CT in the evaluation of retroperitoneal fat tissue infiltration in ductal adenocarcinoma of the pancreatic head: correlation with histopathological findings. *Abdominal Imaging*, **2010**, 35, 465-70		5
5	Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. *PLoS ONE*, **2010**, 5, e10630	3.7	230
4	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, **2009**, 27, 2622-9	2.2	368
3	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. *Laboratory Investigation*, **2008**, 88, 773-84	5.9	29
2	Evaluation of vascular infiltration in resected patients for pancreatic cancer: comparison among multidetector CT, intraoperative findings and histopathology. *Abdominal Imaging*, **2007**, 32, 737-42		6
1	Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. *Cancer Research*, **2006**, 66, 3928-35	10.1	276